Anteris Technologies Ltd
Anteris Technologies Ltd AVR.AX Peers
See (AVR.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AVR.AX | $6.95 | -1.42% | 250.63M | -1.20 | -$5.79 | N/A |
| COH.AX | $265.80 | -0.65% | 17.34B | 46.96 | $5.66 | +1.60% |
| PNV.AX | $1.46 | -0.34% | 1.01B | 146.00 | $0.01 | N/A |
| IMR.AX | $1.70 | -0.29% | 457.95M | -8.47 | -$0.20 | N/A |
| EBR.AX | $1.07 | -6.17% | 395.20M | -5.32 | -$0.20 | N/A |
| AVH.AX | $2.30 | -8.00% | 264.93M | -3.15 | -$0.73 | N/A |
| EMV.AX | $1.84 | -3.93% | 156.92M | -26.21 | -$0.07 | N/A |
| ARX.AX | $0.45 | -3.26% | 153.48M | -22.25 | -$0.02 | N/A |
| CYC.AX | $1.22 | -9.63% | 135.59M | -9.38 | -$0.13 | N/A |
| 4DX.AX | $0.29 | +1.75% | 130.66M | -2.64 | -$0.11 | N/A |
Stock Comparison
AVR.AX vs COH.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, COH.AX has a market cap of 17.34B. Regarding current trading prices, AVR.AX is priced at $6.95, while COH.AX trades at $265.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas COH.AX's P/E ratio is 46.96. In terms of profitability, AVR.AX's ROE is -2.19%, compared to COH.AX's ROE of +0.20%. Regarding short-term risk, AVR.AX is more volatile compared to COH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs PNV.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, PNV.AX has a market cap of 1.01B. Regarding current trading prices, AVR.AX is priced at $6.95, while PNV.AX trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas PNV.AX's P/E ratio is 146.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to PNV.AX's ROE of +0.08%. Regarding short-term risk, AVR.AX is less volatile compared to PNV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs IMR.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, IMR.AX has a market cap of 457.95M. Regarding current trading prices, AVR.AX is priced at $6.95, while IMR.AX trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas IMR.AX's P/E ratio is -8.47. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IMR.AX's ROE of +4.30%. Regarding short-term risk, AVR.AX is less volatile compared to IMR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs EBR.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, EBR.AX has a market cap of 395.20M. Regarding current trading prices, AVR.AX is priced at $6.95, while EBR.AX trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas EBR.AX's P/E ratio is -5.32. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EBR.AX's ROE of -0.91%. Regarding short-term risk, AVR.AX is less volatile compared to EBR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs AVH.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, AVH.AX has a market cap of 264.93M. Regarding current trading prices, AVR.AX is priced at $6.95, while AVH.AX trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas AVH.AX's P/E ratio is -3.15. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AVH.AX's ROE of -0.40%. Regarding short-term risk, AVR.AX is less volatile compared to AVH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs EMV.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, EMV.AX has a market cap of 156.92M. Regarding current trading prices, AVR.AX is priced at $6.95, while EMV.AX trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas EMV.AX's P/E ratio is -26.21. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EMV.AX's ROE of -0.36%. Regarding short-term risk, AVR.AX is less volatile compared to EMV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs ARX.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, ARX.AX has a market cap of 153.48M. Regarding current trading prices, AVR.AX is priced at $6.95, while ARX.AX trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas ARX.AX's P/E ratio is -22.25. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ARX.AX's ROE of -0.08%. Regarding short-term risk, AVR.AX is less volatile compared to ARX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs CYC.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, CYC.AX has a market cap of 135.59M. Regarding current trading prices, AVR.AX is priced at $6.95, while CYC.AX trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas CYC.AX's P/E ratio is -9.38. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CYC.AX's ROE of -0.29%. Regarding short-term risk, AVR.AX is less volatile compared to CYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs 4DX.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, 4DX.AX has a market cap of 130.66M. Regarding current trading prices, AVR.AX is priced at $6.95, while 4DX.AX trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas 4DX.AX's P/E ratio is -2.64. In terms of profitability, AVR.AX's ROE is -2.19%, compared to 4DX.AX's ROE of -0.60%. Regarding short-term risk, AVR.AX is less volatile compared to 4DX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs SOM.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, SOM.AX has a market cap of 108.05M. Regarding current trading prices, AVR.AX is priced at $6.95, while SOM.AX trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas SOM.AX's P/E ratio is -10.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to SOM.AX's ROE of -0.13%. Regarding short-term risk, AVR.AX is less volatile compared to SOM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs IPD.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, IPD.AX has a market cap of 68.93M. Regarding current trading prices, AVR.AX is priced at $6.95, while IPD.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas IPD.AX's P/E ratio is -3.40. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IPD.AX's ROE of -0.58%. Regarding short-term risk, AVR.AX is less volatile compared to IPD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs CMP.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, CMP.AX has a market cap of 54.78M. Regarding current trading prices, AVR.AX is priced at $6.95, while CMP.AX trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas CMP.AX's P/E ratio is -14.25. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CMP.AX's ROE of -0.09%. Regarding short-term risk, AVR.AX is more volatile compared to CMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs RSH.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, RSH.AX has a market cap of 51.98M. Regarding current trading prices, AVR.AX is priced at $6.95, while RSH.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas RSH.AX's P/E ratio is -3.30. In terms of profitability, AVR.AX's ROE is -2.19%, compared to RSH.AX's ROE of -2.03%. Regarding short-term risk, AVR.AX is less volatile compared to RSH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs MX1.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, MX1.AX has a market cap of 41.09M. Regarding current trading prices, AVR.AX is priced at $6.95, while MX1.AX trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas MX1.AX's P/E ratio is -3.20. In terms of profitability, AVR.AX's ROE is -2.19%, compared to MX1.AX's ROE of -1.06%. Regarding short-term risk, AVR.AX is less volatile compared to MX1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs EYE.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, EYE.AX has a market cap of 35.52M. Regarding current trading prices, AVR.AX is priced at $6.95, while EYE.AX trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas EYE.AX's P/E ratio is -3.12. In terms of profitability, AVR.AX's ROE is -2.19%, compared to EYE.AX's ROE of -0.44%. Regarding short-term risk, AVR.AX is less volatile compared to EYE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs CSX.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, CSX.AX has a market cap of 32.82M. Regarding current trading prices, AVR.AX is priced at $6.95, while CSX.AX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas CSX.AX's P/E ratio is -21.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CSX.AX's ROE of -0.08%. Regarding short-term risk, AVR.AX is less volatile compared to CSX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs LBT.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, LBT.AX has a market cap of 29.89M. Regarding current trading prices, AVR.AX is priced at $6.95, while LBT.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas LBT.AX's P/E ratio is -0.42. In terms of profitability, AVR.AX's ROE is -2.19%, compared to LBT.AX's ROE of -1.50%. Regarding short-term risk, AVR.AX is more volatile compared to LBT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs NTI.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, NTI.AX has a market cap of 24.14M. Regarding current trading prices, AVR.AX is priced at $6.95, while NTI.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas NTI.AX's P/E ratio is -2.30. In terms of profitability, AVR.AX's ROE is -2.19%, compared to NTI.AX's ROE of -1.34%. Regarding short-term risk, AVR.AX is less volatile compared to NTI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs CDX.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, CDX.AX has a market cap of 21.07M. Regarding current trading prices, AVR.AX is priced at $6.95, while CDX.AX trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas CDX.AX's P/E ratio is -0.87. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CDX.AX's ROE of -2.72%. Regarding short-term risk, AVR.AX is less volatile compared to CDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs OSL.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, OSL.AX has a market cap of 18.43M. Regarding current trading prices, AVR.AX is priced at $6.95, while OSL.AX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas OSL.AX's P/E ratio is -0.40. In terms of profitability, AVR.AX's ROE is -2.19%, compared to OSL.AX's ROE of -1.97%. Regarding short-term risk, AVR.AX is more volatile compared to OSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs UBI.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, UBI.AX has a market cap of 15.50M. Regarding current trading prices, AVR.AX is priced at $6.95, while UBI.AX trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas UBI.AX's P/E ratio is -1.04. In terms of profitability, AVR.AX's ROE is -2.19%, compared to UBI.AX's ROE of -0.70%. Regarding short-term risk, AVR.AX is less volatile compared to UBI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs HMD.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, HMD.AX has a market cap of 14.89M. Regarding current trading prices, AVR.AX is priced at $6.95, while HMD.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas HMD.AX's P/E ratio is -1.70. In terms of profitability, AVR.AX's ROE is -2.19%, compared to HMD.AX's ROE of -2.84%. Regarding short-term risk, AVR.AX is more volatile compared to HMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs TRU.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, TRU.AX has a market cap of 14.43M. Regarding current trading prices, AVR.AX is priced at $6.95, while TRU.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas TRU.AX's P/E ratio is -2.60. In terms of profitability, AVR.AX's ROE is -2.19%, compared to TRU.AX's ROE of -0.69%. Regarding short-term risk, AVR.AX is more volatile compared to TRU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs RNO.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, RNO.AX has a market cap of 11.47M. Regarding current trading prices, AVR.AX is priced at $6.95, while RNO.AX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas RNO.AX's P/E ratio is -1.00. In terms of profitability, AVR.AX's ROE is -2.19%, compared to RNO.AX's ROE of +15.91%. Regarding short-term risk, AVR.AX is more volatile compared to RNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs AT1.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, AT1.AX has a market cap of 10.98M. Regarding current trading prices, AVR.AX is priced at $6.95, while AT1.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas AT1.AX's P/E ratio is -1.60. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AT1.AX's ROE of -0.74%. Regarding short-term risk, AVR.AX is less volatile compared to AT1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs CBL.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, CBL.AX has a market cap of 10.31M. Regarding current trading prices, AVR.AX is priced at $6.95, while CBL.AX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas CBL.AX's P/E ratio is -1.17. In terms of profitability, AVR.AX's ROE is -2.19%, compared to CBL.AX's ROE of -1.09%. Regarding short-term risk, AVR.AX is less volatile compared to CBL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs IRX.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, IRX.AX has a market cap of 5.76M. Regarding current trading prices, AVR.AX is priced at $6.95, while IRX.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas IRX.AX's P/E ratio is -2.70. In terms of profitability, AVR.AX's ROE is -2.19%, compared to IRX.AX's ROE of +17.09%. Regarding short-term risk, AVR.AX is less volatile compared to IRX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs UCM.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, UCM.AX has a market cap of 5.76M. Regarding current trading prices, AVR.AX is priced at $6.95, while UCM.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas UCM.AX's P/E ratio is -2.30. In terms of profitability, AVR.AX's ROE is -2.19%, compared to UCM.AX's ROE of -0.96%. Regarding short-term risk, AVR.AX is more volatile compared to UCM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs ADR.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, ADR.AX has a market cap of 5.31M. Regarding current trading prices, AVR.AX is priced at $6.95, while ADR.AX trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas ADR.AX's P/E ratio is -0.17. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ADR.AX's ROE of -2.87%. Regarding short-term risk, AVR.AX is more volatile compared to ADR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs OVN.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, OVN.AX has a market cap of 4.83M. Regarding current trading prices, AVR.AX is priced at $6.95, while OVN.AX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas OVN.AX's P/E ratio is -0.40. In terms of profitability, AVR.AX's ROE is -2.19%, compared to OVN.AX's ROE of -0.80%. Regarding short-term risk, AVR.AX is less volatile compared to OVN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs ALT.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, ALT.AX has a market cap of 4.61M. Regarding current trading prices, AVR.AX is priced at $6.95, while ALT.AX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas ALT.AX's P/E ratio is N/A. In terms of profitability, AVR.AX's ROE is -2.19%, compared to ALT.AX's ROE of -2.31%. Regarding short-term risk, AVR.AX is more volatile compared to ALT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs VTI.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, VTI.AX has a market cap of 3.70M. Regarding current trading prices, AVR.AX is priced at $6.95, while VTI.AX trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas VTI.AX's P/E ratio is -0.55. In terms of profitability, AVR.AX's ROE is -2.19%, compared to VTI.AX's ROE of -0.43%. Regarding short-term risk, AVR.AX is more volatile compared to VTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for AVR.AX.
AVR.AX vs AMT.AX Comparison
AVR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVR.AX stands at 250.63M. In comparison, AMT.AX has a market cap of 3.47M. Regarding current trading prices, AVR.AX is priced at $6.95, while AMT.AX trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVR.AX currently has a P/E ratio of -1.20, whereas AMT.AX's P/E ratio is -1.45. In terms of profitability, AVR.AX's ROE is -2.19%, compared to AMT.AX's ROE of -11.52%. Regarding short-term risk, AVR.AX is less volatile compared to AMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AVR.AX.